Sirs-Lab and DXS have announced that they have entered into an EU-wide licensing agreement for the application of Scorpions Technology in the sepsis test Siqnature.
With the selection of the PCR platform technology, Sirs-Lab has completed the technical design of its sepsis prediction and monitoring test, Siqnature.
The test is now accessible for selected scientific experts and will be fully available in 2009.
'The careful review of technologies resulted in the selection of Scorpions to complete the Siqnature product design.
'We will expedite the commercialisation of the test by clinical multi-centre trials with leading international experts,' said chief executive officer of Sirs-Lab Dr Stefan Russwurm.
After the trial phase, Siqnature will be broadly available for clinical routine as part of an integrated diagnostic product concept comprising pathogen detection and monitoring of the host response.
Dr Stephen Little, chief executive officer of DXS, said: 'We are looking forward to seeing Scorpions developed for use in sepsis prediction.
'The high sensitivity, speed and specificity of Scorpions means that it will be ideally suited for applications in the field of infectious diseases.' The molecular diagnostic test Siqnature allows the early detection of sepsis by differentiating between infectious and non-infectious states in hospitalised patients.
